Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 18.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,000 shares of the company's stock after selling 25,000 shares during the quarter. Impax Asset Management Group plc owned approximately 0.11% of Neurocrine Biosciences worth $14,494,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of NBIX. Sunbelt Securities Inc. grew its holdings in Neurocrine Biosciences by 34.3% in the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company's stock worth $37,000 after purchasing an additional 83 shares during the period. Captrust Financial Advisors grew its stake in shares of Neurocrine Biosciences by 3.5% in the 2nd quarter. Captrust Financial Advisors now owns 2,983 shares of the company's stock worth $281,000 after buying an additional 100 shares during the last quarter. Red Spruce Capital LLC grew its stake in shares of Neurocrine Biosciences by 0.6% in the 4th quarter. Red Spruce Capital LLC now owns 16,026 shares of the company's stock worth $2,112,000 after buying an additional 101 shares during the last quarter. Metis Global Partners LLC increased its position in Neurocrine Biosciences by 4.7% during the 3rd quarter. Metis Global Partners LLC now owns 2,361 shares of the company's stock valued at $266,000 after buying an additional 106 shares in the last quarter. Finally, First Republic Investment Management Inc. raised its stake in Neurocrine Biosciences by 1.0% during the fourth quarter. First Republic Investment Management Inc. now owns 11,069 shares of the company's stock valued at $1,322,000 after buying an additional 113 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 5,000 shares of the business's stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the sale, the insider now owns 7,507 shares in the company, valued at $1,088,965.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 2,707 shares of the business's stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total transaction of $380,847.83. Following the sale, the chief executive officer now directly owns 502,188 shares of the company's stock, valued at $70,652,829.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ingrid Delaet sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the completion of the sale, the insider now directly owns 7,507 shares of the company's stock, valued at $1,088,965.42. The disclosure for this sale can be found here. Insiders sold 177,176 shares of company stock worth $24,562,081 in the last quarter. 4.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group raised their price target on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a "buy" rating in a report on Thursday, January 25th. Citigroup dropped their target price on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a "neutral" rating on the stock in a research note on Thursday, February 8th. Wells Fargo & Company boosted their price objective on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an "equal weight" rating in a report on Thursday, February 8th. StockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 8th. Finally, Mizuho upped their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, February 8th. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and an average target price of $139.25.

Neurocrine Biosciences Trading Down 0.6 %

NASDAQ NBIX traded down $0.85 on Wednesday, hitting $138.09. 639,131 shares of the company traded hands, compared to its average volume of 858,210. The business's 50 day moving average price is $136.96 and its 200-day moving average price is $126.05. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37. The company has a market capitalization of $13.74 billion, a price-to-earnings ratio of 57.06, a P/E/G ratio of 0.90 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The company's revenue for the quarter was up 25.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.88 earnings per share. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.83 earnings per share for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.